Xingya Li

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC

Wenfeng Fang, Lin Wu, Xiangjiao Meng et al. · New England Journal of Medicine · 2025 · 40 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Shen Zhao, Ying Cheng, Qiming J. Wang et al. · Nature Medicine · 2025 · 39 citations

Medicine, Oncology, Pharmacology +17

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Yuankai Shi, Jian Fang, Ligang Xing et al. · Nature Medicine · 2025 · 28 citations

Medicine, Molecular Genetics, Oncology +13

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Zhiwei Chen, Fang Yang, Jiang Zhou et al. · The Lancet · 2025 · 28 citations

Medicine, Oncology, Pharmacology +10

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

James Chih‐Hsin Yang, Mengzhao Wang, Yun Fan et al. · Journal of Clinical Oncology · 2025 · 14 citations

Medicine, Oncology, Pharmacology +17